The relative magnitude of transgene-specific adaptive immune responses induced by human and chimpanzee adenovirus vectors differs between laboratory animals and a target species

Vaccine

Volumn 33, Issue 9, 2015, Pages 1121-1128

  Dicks, Matthew D J ^a   Guzman, Efrain ^b   Spencer, Alexandra J ^a   Gilbert, Sarah C ^a   Charleston, Bryan ^b   Hill, Adrian V S ^a   Cottingham, Matthew G ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

Author keywords

Vaccine immunology; Viral vector

Indexed keywords

ADC68 VECTOR; ADENOVIRUS VACCINE; ADENOVIRUS VECTOR; CD8 ANTIGEN; CHADOX1 VECTOR; GAMMA INTERFERON; HUMAN ADENOVIRUS 5 VACCINE; UNCLASSIFIED DRUG; DRUG CARRIER; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CD8+ T LYMPHOCYTE; CHIMPANZEE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSPOT ASSAY; FEMALE; HUMAN; HUMAN ADENOVIRUS 5; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TARGET ORGANISM; TRANSGENE; VACCINATION; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; BOVINE; C57BL MOUSE; COMPARATIVE STUDY; EXPERIMENTAL ANIMAL; GENE VECTOR; GENETICS; IMMUNOLOGY; SECRETION (PROCESS);

ADENOVIRIDAE; ANIMALS; ANIMALS, LABORATORY; CATTLE; CD8-POSITIVE T-LYMPHOCYTES; DRUG CARRIERS; GENETIC VECTORS; INTERFERON-GAMMA; MICE, INBRED BALB C; MICE, INBRED C57BL; RECOMBINANT PROTEINS; TRANSGENES; VACCINES, SYNTHETIC; VIRAL VACCINES;

EID: 84922795840     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.01.042     Document Type: Article

References (46)

1. Alcock R., Cottingham M.G., Rollier C.S., Furze J., De Costa S.D., Hanlon M., et al. Long-term thermostabilization of live poxviral and adenoviral vaccine vectors at supraphysiological temperatures in carbohydrate glass. Sci Transl Med 2010, 2:19ra12.
2. Antrobus R.D., Coughlan L., Berthoud T.K., Dicks M.D., Hill A.V., Lambe T., et al. Clinical assessment of a novel recombinant simian adenovirus ChAdOx1 as a vectored vaccine expressing conserved Influenza A antigens. Mol Ther 2014, 22:668-674.
3. Bachmann M.F., Wolint P., Schwarz K., Jager P., Oxenius A. Functional properties and lineage relationship of CD8+ T cell subsets identified by expression of IL-7 receptor alpha and CD62L. Journal of immunology (Baltimore, Md: 1950) 2005, 175:4686-4696.
4. Bassett J.D., Yang T.C., Bernard D., Millar J.B., Swift S.L., McGray A.J., et al. CD8+ T-cell expansion and maintenance after recombinant adenovirus immunization rely upon cooperation between hematopoietic and nonhematopoietic antigen-presenting cells. Blood 2011, 117:1146-1155.
5. Betts M.R., Nason M.C., West S.M., De Rosa S.C., Migueles S.A., Abraham J., et al. HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 2006, 107:4781-4789.
6. Biswas S., Dicks M.D., Long C.A., Remarque E.J., Siani L., Colloca S., et al. Transgene optimization, immunogenicity and in vitro efficacy of viral vectored vaccines expressing two alleles of Plasmodium falciparum AMA1. PLoS ONE 2011, 6:e20977.
7. Chen H., Xiang Z.Q., Li Y., Kurupati R.K., Jia B., Bian A., et al. Adenovirus-based vaccines: comparison of vectors from three species of adenoviridae. J Virol 2010, 84:10522-10532.
8. Colloca S., Barnes E., Folgori A., Ammendola V., Capone S., Cirillo A., et al. Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 2012, 4:115ra112.
9. Cottingham M.G., Andersen R.F., Spencer A.J., Saurya S., Furze J., Hill A.V.S., et al. Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA). PLoS ONE 2008, 3:e1638.
10. Cubillos-Zapata C., Guzman E., Turner A., Gilbert S.C., Prentice H., Hope J.C., et al. Differential effects of viral vectors on migratory afferent lymph dendritic cells in vitro predict enhanced immunogenicity in vivo. J Virol 2011, 85:9385-9394.
11. Darrah P.A., Patel D.T., De Luca P.M., Lindsay R.W., Davey D.F., Flynn B.J., et al. Multifunctional TH1 cells define a correlate of vaccine-mediated protection against Leishmania major. Nat Med 2007, 13:843-850.
12. Dean G., Whelan A., Clifford D., Salguero F.J., Xing Z., Gilbert S., et al. Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines. Vaccine 2014, 32:1304-1310.
13. Dicks M.D., Spencer A.J., Edwards N.J., Wadell G., Bojang K., Gilbert S.C., et al. A novel chimpanzee adenovirus vector with low human seroprevalence: improved systems for vector derivation and comparative immunogenicity. PLoS ONE 2012, 7:e40385.
14. Draper S.J., Heeney J.L. Viruses as vaccine vectors for infectious diseases and cancer. Nat Rev Microbiol 2010, 8:62-73.
15. Draper S.J., Moore A.C., Goodman A.L., Long C.A., Holder A.A., Gilbert S.C., et al. Effective induction of high-titer antibodies by viral vector vaccines. Nat Med 2008, 14:819-821.
16. Ferreira T.B., Alves P.M., Aunins J.G., Carrondo M.J. Use of adenoviral vectors as veterinary vaccines. Gene Ther 2005, 12(Suppl. 1):S73-S83.
17. Hensley S.E., Cun A.S., Giles-Davis W., Li Y., Xiang Z., Lasaro M.O., et al. Type I interferon inhibits antibody responses induced by a chimpanzee adenovirus vector. Mol Ther 2007, 15:393-403.
18. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010, 6:78-83.
19. Larsen K.C., Spencer A.J., Goodman A.L., Gilchrist A., Furze J., Rollier C.S., et al. Expression of tak1 and tram induces synergistic pro-inflammatory signalling and adjuvants DNA vaccines. Vaccine 2009, 27:5589-5598.
20. Maizel J.V., White D.O., Scharff M.D. The polypeptides of adenovirus I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. Virology 1968, 36:115-125.
21. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372:1894-1905.
22. McShane H., Behboudi S., Goonetilleke N., Brookes R., Hill A.V.S. Protective immunity against Mycobacterium tuberculosis induced by dendritic cells pulsed with both CD8(+)- and CD4(+)-T-cell epitopes from antigen 85A. Infect Immun 2002, 70:1623-1626.
23. Montiel N.A., Smoliga G., Arzt J. Time-dependent biodistribution and transgene expression of a recombinant human adenovirus serotype 5-luciferase vector as a surrogate for rAd5-FMDV vaccines in cattle. Vet Immunol Immunopathol 2013, 151:37-48.
24. Moraes M.P., Segundo F.D., Dias C.C., Pena L., Grubman M.J. Increased efficacy of an adenovirus-vectored foot-and-mouth disease capsid subunit vaccine expressing nonstructural protein 2B is associated with a specific T cell response. Vaccine 2011, 29:9431-9440.
25. Mullarkey C.E., Boyd A., van Laarhoven A., Lefevre E.A., Carr B.V., Baratelli M., et al. Improved adjuvanting of seasonal influenza vaccines: pre-clinical studies of MVA-NP+M1 co-administration with inactivated influenza vaccine. Eur J Immunol 2013, 43(7):1940-1952.
26. O'Hara G.A., Duncan C.J., Ewer K.J., Collins K.A., Elias S.C., Halstead F.D., et al. Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector. J Infect Dis 2012, 205(5):772-781.
27. Pacheco J.M., Brum M.C., Moraes M.P., Golde W.T., Grubman M.J. Rapid protection of cattle from direct challenge with foot-and-mouth disease virus (FMDV) by a single inoculation with an adenovirus-vectored FMDV subunit vaccine. Virology 2005, 337:205-209.
28. Pinto A.R., Fitzgerald J.C., Giles-Davis W., Gao G.P., Wilson J.M., Ertl H.C.J. Induction of CD8+ T cells to an HIV-1 antigen through a prime boost regimen with heterologous E1-deleted adenoviral vaccine carriers. J Immunol (Baltimore, Md: 1950) 2003, 171:6774-6779.
29. Quinn K.M., Da Costa A., Yamamoto A., Berry D., Lindsay R.W., Darrah P.A., et al. Comparative analysis of the magnitude, quality, phenotype, and protective capacity of simian immunodeficiency virus gag-specific CD8+ T cells following human-, simian-, and chimpanzee-derived recombinant adenoviral vector immunization. J Immunol 2013, 190:2720-2735.
30. Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., et al. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 2008, 38:732-741.
31. Roederer M., Nozzi J.L., Nason M.C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011, 79:167-174.
32. Roy S., Vandenberghe L.H., Kryazhimskiy S., Grant R., Calcedo R., Yuan X., et al. Isolation and characterization of adenoviruses persistently shed from the gastrointestinal tract of non-human primates. PLoS Pathog 2009, 5:e1000503.
33. Schirmbeck R., Reimann J., Kochanek S., Kreppel F. The immunogenicity of adenovirus vectors limits the multispecificity of CD8 T-cell responses to vector-encoded transgenic antigens. Mol Ther 2008, 16:1609-1616.
34. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat Rev Immunol 2008, 8:247-258.
35. Sheehy S.H., Duncan C.J., Elias S.C., Biswas S., Collins K.A., O'Hara G.A., et al. Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors. PLoS ONE 2012, 7:e31208.
36. Sheehy S.H., Duncan C.J., Elias S.C., Collins K.A., Ewer K.J., Spencer A.J., et al. Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors. Mol Ther 2011, 19:2269-2276.
37. Spencer A.J., Hill F., Honeycutt J.D., Cottingham M.G., Bregu M., Rollier C.S., et al. Fusion of the Mycobacterium tuberculosis antigen 85A to an oligomerization domain enhances its immunogenicity in both mice and non-human primates. PLoS ONE 2012, 7:e33555.
38. Sridhar S., Reyes-Sandoval A., Draper S.J., Moore A.C., Gilbert S.C., Gao G.P., et al. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A. J Virol 2008, 82:3822-3833.
39. Tameris M.D., Hatherill M., Landry B.S., Scriba T.J., Snowden M.A., Lockhart S., et al. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 2013, 381:1021-1028.
40. Tatsis N., Ertl H.C.J. Adenoviruses as vaccine vectors. Mol Ther 2004, 10:616-629.
41. Tatsis N., Fitzgerald J.C., Reyes-Sandoval A., Harris-McCoy K.C., Hensley S.E., Zhou D., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007, 110:1916-1923.
42. Tatsis N., Tesema L., Robinson E.R., Giles-Davis W., McCoy K., Gao G.P., et al. Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 2006, 13:421-429.
43. Vordermeier H.M., Huygen K., Singh M., Hewinson R.G., Xing Z. Immune responses induced in cattle by vaccination with a recombinant adenovirus expressing Mycobacterial antigen 85A and Mycobacterium bovis BCG. Infect Immun 2006, 74:1416-1418.
44. Yang T.C., Millar J., Groves T., Grinshtein N., Parsons R., Takenaka S., et al. The CD8+ T cell population elicited by recombinant adenovirus displays a novel partially exhausted phenotype associated with prolonged antigen presentation that nonetheless provides long-term immunity. J Immunol 2006, 176:200-210.
45. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 1999, 17:51-88.
46. Zakhartchouk A.N., Pyne C., Mutwiri G.K., Papp Z., Baca-Estrada M.E., Griebel P., et al. Mucosal immunization of calves with recombinant bovine adenovirus-3: induction of protective immunity to bovine herpesvirus-1. J Gen Virol 1999, 80((Pt 5):):1263-1269.